Tandem Diabetes Care (TNDM) Share-based Compensation Growth (1y) (2014 - 2026)
Tandem Diabetes Care (TNDM) Share-based Compensation Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.69% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 37.62% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 6.74% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 12.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 12.94% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -30.44% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 59.09% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Tandem Diabetes Care | 1.16 Bn | 587.46 Mn | 136.79 Mn | -38.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.56% |
| Sep 30, 2025 | 34.15% |
| Jun 30, 2025 | -42.56% |
| Mar 31, 2025 | 1,011.12% |
| Dec 31, 2024 | 4.85% |
| Sep 30, 2024 | 15.00% |
| Jun 30, 2024 | 90.78% |
| Mar 31, 2024 | -89.18% |
| Dec 31, 2023 | 260.36% |
| Sep 30, 2023 | 10.88% |
| Jun 30, 2023 | -74.68% |
| Mar 31, 2023 | 17.03% |
| Dec 31, 2022 | -46.48% |
| Sep 30, 2022 | -289.80% |
| Jun 30, 2022 | 516.98% |
| Mar 31, 2022 | 39.88% |
| Sep 30, 2021 | -679.03% |
| Jun 30, 2021 | 312.14% |
| Mar 31, 2021 | -18.39% |
| Sep 30, 2020 | -92.07% |